The leucine-rich repeat-containing protein 15 (LRRC15) is a cell surface protein involved in cell-cell and cell-matrix interactions, with limited expression in normal tissues.
Sotio Biotech AS is exercising an option under a license and option agreement to obtain a license to Synaffix BV’s technology to develop two bispecific antibody-drug conjugate (ADC) programs for solid tumors.
Within the immune system, interleukin-15 (IL-15) plays a relevant role by boosting the number of cytotoxic T cells and NK cells, the major drivers of anticancer immune response. Researchers from Sotio Biotech AS, MD Anderson and collaborators reported preclinical data on nanrilkefusp alfa (nanril; SOT-101), an IL-15 receptor βγ superagonist that stimulates both CD8+ T and NK cells in the tumor microenvironment.
Sotio Biotech AS and Biocytogen Pharmaceuticals Co. Ltd. are partnering to discover antibody-drug conjugates (ADCs) via an option and license agreement worth up to $325.5 million plus sales royalties. The deal grants Sotio of Prague, Czech Republic, the option to license multiple fully human bispecific antibodies generated with Biocytogen’s Renlite platform, which Sotio will use to develop next-generation ADCs targeting solid tumors.
Sotio Biotech AS and Biocytogen Pharmaceuticals Co. Ltd. are partnering to discover antibody-drug conjugates (ADCs) via an option and license agreement worth up to $325.5 million plus sales royalties. The deal grants Sotio of Prague, Czech Republic, the option to license multiple fully human bispecific antibodies generated with Biocytogen’s Renlite platform, which Sotio will use to develop next-generation ADCs targeting solid tumors.
Sotio Biotech AS, a company owned by PPF Group, has entered into a license and option agreement with Synaffix BV, a Lonza company, to develop next-generation antibody-drug conjugates (ADCs) for the treatment of solid tumors.
Sotio Biotech AS has exercised its first of five exclusive, target-specific options with Legochem Biosciences Inc. for antibody-drug conjugate (ADC) SOT-106, which is currently being evaluated in preclinical studies in multiple solid tumor indications.
Sotio Biotech AS has licensed Legochem Biosciences Inc.’s technology for five new antibody-drug conjugates (ADC) in a deal that could bring the latter over $1 billion. Prague, Czech Republic-based Sotio will have the rights to deploy Legochem’s Conjuall and potent linker-payload platform, including multiple different payloads, for five therapeutic programs targeting solid tumors and combine its proprietary antibodies with it.
Sotio Biotech AS has licensed Legochem Biosciences Inc.’s technology for five new antibody-drug conjugates (ADC) in a deal that could bring the latter over $1 billion.
